FLGT Stock Risk & Deep Value Analysis

Fulgent Genetics Inc

DVR Score

2.1

out of 10

Risk Trap

The Bottom Line on FLGT

We analyzed Fulgent Genetics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran FLGT through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Feb 27, 2026•Run Fresh Analysis →

📈FLGT Performance Overview3yr weekly

📊

Unlock FLGT Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

FLGT Stock Risk Analysis

Overall Risk

Aggressive

Financial Risk

Medium

Market Risk

High

FLGT Deep Value Analysis

Fulgent Genetics (FLGT) presents a highly speculative opportunity for 10x growth, with a current score of 21/100 reflecting extremely low, but not zero, probability. The company holds a significant cash reserve, enabling strategic acquisitions like Inform Diagnostics to diversify into broader pathology and precision medicine. This pivot provides a potential platform for growth in the vast genetic testing TAM. However, the path to market leadership is unclear amid fierce competition and reimbursement complexities. While management has shown adaptability post-COVID, execution of the new strategy to achieve exponential organic growth remains unproven. Catalysts are incremental rather than transformative for a 10x outcome, and sentiment remains cautious. Red flags include intense competition and the challenge of converting strategic assets into dominant market share.

Compare FLGT to Similar Stocks

See how Fulgent Genetics Inc stacks up against related companies in our head-to-head analysis.

FLGT vs ARKG

Compare →

FLGT vs ILMN

Compare →

FLGT Red Flags & Warning Signs

Premium

⚠
Disappointing Q4 2025 earnings guidance or slower-than-expected core genomics growth
⚠
Increased competitive pressure or pricing wars in key diagnostic segments
⚠
Unfavorable changes in reimbursement policies for advanced genetic testing

Unlock FLGT Red Flags & Risk Warnings

Premium members see every risk event we found.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

FLGT Competitive Moat Analysis

Premium

Moat Rating

Narrow

Moat Trend

Stable

Moat Sources

3 Identified

Intangible Assets/IPSwitching CostsCost Advantages

Fulgent's moat, derived from its proprietary technology and test menu, is vulnerable to rapid advancements by competitors and pricing pressures. While the Inform Diagnostics acquisition adds a pathology network and customer stickiness, the core genomic testing market remains highly competitive, requiring continuous innovation to maintain relevance.

FLGT Competitive Moat Analysis

Premium unlocks moat rating, sources & durability.

FLGT Catalysts & Growth Drivers

Near-Term (0-6 months)

•Q4 2025 Earnings Report (Estimated Early-March 2026)
•Updates on Inform Diagnostics integration and cross-selling synergies

Medium-Term (6-18 months)

•Launch of new advanced genomic tests (e.g., refined liquid biopsy assays) with initial adoption data
•Strategic partnerships to expand market access for genomic/pathology services

Long-Term (18+ months)

•Significant traction in population genomics initiatives or large-scale screening programs
•Broader adoption and favorable reimbursement for AI-driven diagnostic insights

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

FLGT Bull Case: What Could Go Right

✓
Acceleration in year-over-year core genomics revenue growth (non-COVID)
✓
Demonstrated successful integration and cross-selling synergies from Inform Diagnostics
✓
Consistent improvement in gross margins and a clear path to sustained profitability

Bull Case Analysis

See what could go right with Premium

🔔

Never miss a move on FLGT

Create a free account to set price alerts and get notified on Telegram when FLGT hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Fulgent Genetics Inc (FLGT)?

As of February 27, 2026, Fulgent Genetics Inc has a DVR Score of 2.1 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the risk level for FLGT stock?

Our analysis rates Fulgent Genetics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

How often is the FLGT DVR analysis updated?

Our AI-powered analysis of Fulgent Genetics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on February 27, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.